129 related articles for article (PubMed ID: 15461062)
21. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study.
Altstaedt HO; Berzewski B; Breddin HK; Brockhaus W; Bruhn HD; Cachovan M; Diehm C; Dörrler J; Franke CS; Gruss JD
Prostaglandins Leukot Essent Fatty Acids; 1993 Aug; 49(2):573-8. PubMed ID: 7692455
[TBL] [Abstract][Full Text] [Related]
22. Effect of prostaglandin E1 on blood flow in normal and ischemic canine hindlimbs.
Pasch AR; Ricotta JJ; Burke AR; O'Mara RE; DeWeese JA; Wilson G
Surgery; 1984 Jun; 95(6):724-9. PubMed ID: 6539509
[TBL] [Abstract][Full Text] [Related]
23. Intensive vascular training in stage IIb of peripheral arterial occlusive disease. The additive effects of intravenous prostaglandin E1 or intravenous pentoxifylline during training.
Scheffler P; de la Hamette D; Gross J; Mueller H; Schieffer H
Circulation; 1994 Aug; 90(2):818-22. PubMed ID: 8044953
[TBL] [Abstract][Full Text] [Related]
24. [Results of the treatment of peripheral arterial diseases with PGE1].
Borkowski M; Kruk M; Królicki L; Wojtal E; Malmurowicz L; Górewicz R; Laszuk D
Pol Tyg Lek; 1990 Jun 18-25; 45(25-26):505-8. PubMed ID: 2287566
[TBL] [Abstract][Full Text] [Related]
25. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study.
Bode-Böger SM; Böger RH; Alfke H; Heinzel D; Tsikas D; Creutzig A; Alexander K; Frölich JC
Circulation; 1996 Jan; 93(1):85-90. PubMed ID: 8616947
[TBL] [Abstract][Full Text] [Related]
26. [Risk-benefit analysis of intra-arterial and intravenous PGE1 infusions in peripheral arterial occlusive disorders].
Heidrich H
Vasa Suppl; 1991; 33():346-7. PubMed ID: 1788752
[TBL] [Abstract][Full Text] [Related]
27. [Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
Hesse WH; Rudofsky G; Peskar BA
Wien Klin Wochenschr; 1991; 103(18):554-7. PubMed ID: 1750222
[TBL] [Abstract][Full Text] [Related]
28. Study of thrombinic activation indexes, in patients with lower limb critic ischaemia, before and after prostaglandin E1 therapy.
Trifiletti A; Bartolone S; Scamardi R; Pizzoleo MA; Attinà A; Sottilotta G; Canobbio V; Soraci S; Barbera N
Minerva Cardioangiol; 1999 Mar; 47(3):55-8. PubMed ID: 10389444
[TBL] [Abstract][Full Text] [Related]
29. Are there predictors for the outcome of a PGE1 treatment in peripheral arterial disease with critical limb ischaemia?
Heidrich H; Schmidt T; Fahrig C
Vasa; 2005 May; 34(2):101-7. PubMed ID: 15968891
[TBL] [Abstract][Full Text] [Related]
30. Vasodilator actions of prostaglandin 6-keto-E1 in the pulmonary vascular bed.
Hyman AL; Kadowitz PJ
J Pharmacol Exp Ther; 1980 Jun; 213(3):468-72. PubMed ID: 7193724
[TBL] [Abstract][Full Text] [Related]
31. Hemostatic and fibrinolytic effects of systemic prostaglandin E1 therapy in patients with peripheral arterial disease.
Kuss M; Heidrich H; Koettgen E
Vasa; 2003 Aug; 32(3):145-8. PubMed ID: 14524034
[TBL] [Abstract][Full Text] [Related]
32. Intraarterial prostaglandine E1 in arterial occlusive disease (AOD) stages III and IV.
Herold A; Bruch HP; Hörl M; Düsel W
Prog Clin Biol Res; 1987; 242():439-44. PubMed ID: 2959966
[TBL] [Abstract][Full Text] [Related]
33. Peripheral arterial disease: drug therapy.
Schwartz JB
J Gend Specif Med; 2002; 5(4):16-20. PubMed ID: 12192882
[No Abstract] [Full Text] [Related]
34. Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow.
Schellong SM; Burchert W; Böger RM; Creutzig A; Hundeshagen H; Alexander K
Scand J Clin Lab Invest; 1998 Apr; 58(2):109-17. PubMed ID: 9587162
[TBL] [Abstract][Full Text] [Related]
35. [Prostaglandin E1 in therapy of peripheral arterial occlusive disease].
Sinzinger H; Rogatti W
Wien Klin Wochenschr; 1991; 103(18):558-65. PubMed ID: 1750223
[TBL] [Abstract][Full Text] [Related]
36. [Placebo controlled study of the effect of intravenous PGE1 on macro- and microcirculation in patients with stage III/IV arterial occlusive disease].
Scheffler P; de la Hamette D; Leipnitz G
Vasa Suppl; 1991; 33():343-4. PubMed ID: 1788750
[TBL] [Abstract][Full Text] [Related]
37. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.
Chirkov YY; Chirkova LP; Sage RE; Horowitz JD
J Cardiovasc Pharmacol; 1995 Jun; 25(6):961-6. PubMed ID: 7564342
[TBL] [Abstract][Full Text] [Related]
38. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience.
Porst H
J Urol; 1996 Mar; 155(3):802-15. PubMed ID: 8583582
[TBL] [Abstract][Full Text] [Related]
39. [Administration of prostaglandin E1 in the treatment of patients with chronic lower limbs critical ischemia with concomitant ischemic heat disease].
Krotovskiĭ GS; Zudin AM; Kotov AE; Uchkin IG; Zasorina MA; Mosesov AG
Khirurgiia (Mosk); 2004; (3):31-4. PubMed ID: 15097985
[TBL] [Abstract][Full Text] [Related]
40. Alprostadil: modes of actions in peripheral arterial occlusive disease.
Karetova D; Bultas J; Vondracek V; Aschermann M
Am J Ther; 1997; 4(11-12):359-63. PubMed ID: 10423631
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
